Siobhán Hayes - Concepedia

Author

Siobhán Hayes

Research Triangle Park Foundation

Also Known As

S HAYES, S Hayes, S. Hayes, Siobhan C. Hayes, Siobhan Hayes, Siobhán Hayes

Publications

377

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)Icon (United Kingdom)

About

Siobhán Hayes is an author at Research Triangle Park Foundation specializing in medicine, thrombosis, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	93
2	Health Sciences	1	1	20
3	Public Health	1	1	41
4	Biomedical Engineering	1	1	21
5	Epidemiology	1	1	41

Siobhán Hayes

Publications

312

Citations

H-Index

Page 1

	Year	Citations
Population pharmacokinetics of dolutegravir in HIV‐infected treatment‐naive patients Jianping Zhang, Siobhán Hayes, Brian M. Sadler, British Journal of Clinical Pharmacology	2015	80
In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step Tom O’Hara, Siobhán Hayes, John D. Davis, Journal of Pharmacokinetics and Pharmacodynamics	2001	57
Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing Siobhán Hayes, Danièle Ouellet, Jianping Zhang, The Journal of Clinical Pharmacology ImmunologyItp PatientsPharmacotherapyImmunotherapyPhysiologically-based Pharmacokinetic Modeling	2010	41
Population pharmacokinetics of recombinant human <scp>C1</scp> inhibitor in patients with hereditary angioedema Colm Farrell, Siobhán Hayes, Anurag Relan, British Journal of Clinical Pharmacology	2013	31
Population Pharmacokinetics of Extended-Release Injectable Naltrexone (XR-NTX) in Patients With Alcohol Dependence Joi Dunbar, Ryan Z. Turncliff, Siobhán Hayes, Journal of Studies on Alcohol and Drugs	2007	22
Interpretation and Optimization of the Dissolution Specifications for a Modified Release Product with an In Vivo–In Vitro Correlation (IVIVC) Siobhán Hayes, Adrian Dunne, Trevor Smart, Journal of Pharmaceutical Sciences Pharmaceutical ScienceModified Release ProductMedicinePharmaceutical TechnologyDrug Delivery Systems	2004	21
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia Siobhán Hayes, Paul N. Mudd, Danièle Ouellet, Cancer Chemotherapy and Pharmacology ThrombopoiesisThrombosisHealth SciencesChemotherapy-induced ThrombocytopeniaMedicine	2013	20
Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease Colm Farrell, Siobhán Hayes, Mary Beth Wire, British Journal of Clinical Pharmacology	2013	15
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <i>BRAF</i> V600–mutant tumours Noelia Nebot, Hendrik‐Tobias Arkenau, Jeffrey R. Infante, British Journal of Clinical Pharmacology	2017	14
Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia Kai Wu, Mita Thapar, Colm Farrell, Clinical Therapeutics Population PharmacokineticThrombosisThrombopoiesisVenous ThrombosisBlood Platelet	2015	11

Page 1